Acute Repetitive Seizures Market Size, Share By Product (NRL-1, Diastat Rectal Gel, USL-261, AZ-002 and Others) - Global Industry Analysis, Trends, Segment Forecasts, Regional Outlook 2023 - 2032


The global acute repetitive seizures market size accounted for USD 0.52 billion in 2022, and it is expected to hit around USD 19.49 billion by 2032, poised to grow at a CAGR of 44.2% from 2023 to 2032.

Acute Repetitive Seizures Market Size 2023 to 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Growth Factors

Emergence routes of administration for epileptic seizures, novel drug treatments and genetic factors related with brain malformations & epileptic seizures are few of the major influences stimulating the growth of epileptic seizures treatment market across the globe. Furthermore, upsurge in occurrence of head injuries, cardiovascular diseases, brain cancer, substance abuse and infections accelerate the demand for epileptic seizures treatment worldwide.

Upsurge in patient populace with status epilepticus and acute repetitive seizures are the main reason bolstering the development of the epileptic seizures treatment market. High unmet clinical requirements for patients along with caregivers, and obtainability of cutting-edge product pipeline are certain foremost influences predicted to push market growth. Drug therapy is operative for most of the patients undergoing from cluster seizures. Yet, there are a substantial amount of treatment issues and unmet medical requirements such as adversative reactions, drug-induced seizures, and deficiency of antiepileptogenic agents that can avert the growth of seizures and its comorbidities. Ratio of acute treatment successes and route of administration are crucial drivers of physicians’ recommending decisions and/or are the emphasis of drug development for novel ARS therapies.

Product Insights

On the basis of product, acute repetitive seizures market is classified into Diastat Rectal Gel, NRL-1, USL-261, AZ-002, and others. Among all, Diastat Rectal Gel controlled majority of the revenue stake in 2022 due to its competence and absence of FDA-approved drugs in the marketplace. It is the solitary FDA-approved drug and the generic forms of it were announced in 2010. Amongst the numerous routes of medicine administration, patients favor the intra-nasal route over other kinds including rectal, buccal, and intramuscular route. Parenteral medications have confirmed to be the optimum choice for outpatient treatment. Yet, in few nations like the Netherlands, caregivers are not competent for managing parenteral medications.

Regional Insights

North America garnered foremost share of the global acute repetitive seizures and epileptic seizures treatment market in 2022. This growth is credible to escalation in occurrence of neurological disorders, current drug approvals, surge in brain injuries, and deep-rooted healthcare structure. North America is likely to continue this trend during the estimate period. Further, acute repetitive seizures market in Europe is expected to advance at a rapid pace from owing to upsurge in investment R&D in the area of neurology, upsurge in funds presented by the government, and escalation in requirement for medications for epilepsy.

As per data released by National Center for Biotechnology Information, in February 2016, U.S. Library of Medicine specified that each year 50,000 to 150,000 individuals in the U.S. affected with status epilepticus, with mortality projected at less than 3% in kids, nonetheless around 30% in adults. Asia Pacific is expected to develop at a higher growth rate within the estimate period, due to greater epilepsy patient population, intensification in alertness about epileptic seizures, upsurge in emphasis on refining healthcare infrastructure, upsurge in elderly population, and increasing number of market participants reinforcing their footmark in the region.

Furthermore,growing in consciousness about the treatment of neurological disorders and upsurge in requirement for novel drug formulations for treating critical situations in neurology are further boosting the market growth in this region.

Key Companies & Market Share Insights

New-fangled product advancement with novel route of administration, acquisitions, mergers and tactical associations, distribution tie-ups, and augmented research & development spending are the key approaches implemented by top players in the global acute repetitive seizures treatment market.The acute repetitive seizures market is motivated by an intensification in the number of pharmaceutical players involved in new-fangled drug development and upsurge in pervasiveness of epileptic seizures.

  • In September 2018, Neurelis, Inc., a pharmaceutical company submitted a New Drug NDA to the FDA for a treatment for epilepsy patients with acute repetitive seizures named VALTOCO.
  • In January 2020, Neurelis, stated that the U.S. FDA has legalized diazepam nasal spray named VALTOCO® as an acute treatment of intermittent, stereotypic episodes of recurrent seizure movement that are dissimilar from a patient’s general seizure pattern in persons with epilepsy 6 years of age and older. The exclusive formulation of VALTOCO includesIntravail® for reliable and consistent absorption.
  • In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company’s latest anti-epileptic drug (AED) NAYZILAM® nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient’s normal seizure form in person with epilepsy 12 years and older1. NAYZILAM delivers caregivers and patients with the foremost and only FDA-approved nasal selection for treating seizure clusters.

Acute Repetitive Seizures Market Companies

  • Neurelis, Inc.
  • UCB S.A.
  • Valeant Pharmaceuticals North America LLC
  • Alexza Pharmaceuticals
  • Others

Acute Repetitive Seizures Market Scope

Report Highlights Details
Market Size in 2023 USD 0.52 Billion
Market Size by 2032 USD 19.49 Billion
Growth Rate from 2023 to 2032 CAGR of 44.2%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product Type, Region Type
Companies Mentioned Neurelis, Inc., UCB S.A., Valeant Pharmaceuticals North America LLC, Alexza Pharmaceuticals, Others

 

Segments Covered in the Report

This research report includes complete valuation of the market by means of extensive qualitative and quantitative perceptions, and projections concerning the market. This report offers breakdown of market into forthcoming and niche sectors. Further, this research study calculates market revenue and its growth trend at global, regional, and country from 2020 to 2032. This report includes market breakdown and its revenue estimate by classifying it on the basis of product and region as follows:

Product Outlook

  • NRL-1
  • Diastat Rectal Gel
  • USL-261
  • AZ-002
  • Others

Regional Outlook

  • North America
    • U.S.
    • Canada    
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • North Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the acute repetitive seizures market growth?
The global acute repetitive seizures market is anticipated to grow at a CAGR of 44.2% throughout forecast period 2023 - 2032.
How much is the acute repetitive seizures market size?
Precedence Research says the global acute repetitive seizures market size is expected to hit around US$ 19.49 billion by 2032.
Which region garnered foremost share of the global acute repetitive seizures and epileptic seizures treatment market?
North America garnered foremost share of the global acute repetitive seizures and epileptic seizures treatment market in 2022.
Why Asia Pacific is expected to expand at fastest CAGR in the acute repetitive seizures market?
The market in the Asia Pacific is expected to expand at fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology.
Which factors driving the acute repetitive seizures market?
Increase in the number of clinical trials, a rise in emphasis on the introduction of new therapies, and the rise in requirement for nasal sprays for the treatment of epilepsy are the foremost reason influencing the development of acute repetitive seizures market across the globe. Furthermore, an intensification in the amount of supervisory approvals and promising drugs in the pipeline is expected to boost the growth of the acute repetitive seizures market within the prediction period.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample